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CHAPTER TWENTY -TWO 
Division of Clinical 
Pharmacology 
WILLIAM B. ABRAMS, M.D. AND PETER H. VLASSES, PHARM. D. 
"The Lord hath created medicines out of 
the earth; and he that is wise will not 
abhor them.J) 
C LINICAL pharmacology is the study of drugs in man. Its two principal components are drug disposition (the effect 
of the body on the drug) and pharmacodynamics 
(the eHect of tile drug on the body). These broad 
categories have been expanded and combined over 
the years so that investigations reported under this 
label have ranged from receptor studies to 
controlled clinical trials. 
The discipline of clinical pharmacology emerged 
in tilis country in the 19505, led by studies of 
cardiovascular drugs by Harry Gold at Cornell and 
of human drug metabolism at the Goldwater 
Memorial Hospital in New York City, and by 
cardiovascular pharmacology progran1s at the 
National Institutes of Health. Academic clinical 
pharmacology units appeared at Johns Hopkins, 
Emory, Kansas, Yale, Vanderbilt, and many other 
wliversities. The study of drugs in man is, of 
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course, of prime interest to the pharmaceutical 
industry. Industry-sponsored clinical pharmacology 
programs thus came on the scene at the same 
time, modeled after the Lilly unit in Indianapolis, 
which had been in operation since 1927. Other 
successful early units were sponsored by Hoffmann-
La Roche, Upjohn, and Parke-Davis. 
Clinical Pharmacology at 
Jefferson 
Clinical pharmacology, as a special field, was 
introduced to Jefferson in 1966. In that year, the 
Smith, Kline & French Foundation provided 
fWlds to develop a joint Division of Clinical 
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Pharmacology in the Departments of Medicine 
and Pharmacology. Dr. John Capelli (Jefferson, 
1962) was appointed Director in 1968. 
Dr. Capelli pursued his fellowship training at 
the Michael Reese Hospital and Jefferson. 
Following his year as Chief Medical Resident, he 
was appointed Director of the Division of Clinical 
Pharmacology and a member of the Division of 
Nephrology. Dr. Lawrence Wesson was made a 
member of the Division of Clinical Pharmacology 
at that time. 
Unfortunately, 1968 and 1969 were difficult years 
in the development of the medical practice plan 
for members of the full-time Faculty of the 
Clinical Departments at Jefferson. Dr. Capelli 
decided to resign his full-time position as Director 
of the Division of Clinical Pharmacology and 
enter private medical practice. Dr. Wesson was 
then appointed Director. Other members of the 
Division at that time were Drs. Peter Amadio of 
Wallace Laboratories, Elmer Funk, Jr., and 
Thomas N. Gates of Merck Sharp & Dohme, and 
Charles K. Gorby of Lankenau Hospital. This 
original Division of Clinical Pharmacology 
continued through June 30, 1973, when it was 
discontinued because of lack of financial support. 
The Present Clinical 
Pharmacology Division 
The present Clinical Pharmacology Program began 
in 1975 when senior officers of the Merck Sharp & 
Dohme Research Laboratories (MSDRL) 
approached their counterparts as Thomas Jefferson 
University with a proposal for a collaborative 
clinical pharmacology venture. The proposed 
arrangement had a number of unique 
characteristics. Unlike units funded by other 
pharmaceutical companies elsewhere, the 
administration and staffmg of the Jefferson Unit 
would be entirely under the control of the 
University even though the major portion of the 
financial support would come from MSDRL. An 
advisory committee with representatives from both 
institutions initially oversaw the function and 
direction of the Unit. Although the major Unit 
effort would be committed to MSDRL studies, 
other projects from a variety of funding sources 
could be undertaken. The Unit would be a 
Division of the Department of Medicine and be 
located on the fifth floor of the 1907 Main 
Hospital Building. A letter of understanding that 
included these provisions was signed by officers 
from both institutions in December of 1976. 
Jefferson officials prominent in these early 
negotiations were Dr. Francis J. Sweeney, Jr., Vice-
President, Medical Affairs; Dr. William Kellow, 
Dean of Jefferson Medical College; Mr. Byron 
Irwin, Associate Administrator, Thomas Jefferson 
University Hospital; Dr. Frank D. Gray, 
Chairman and Professor of Medicine; and Dr. 
C. Paul Bianchi, Chairman and Professor of 
Pharmacology. MSDRL was represented by Dr. 
William B. Abrams (Jefferson, 194-7), Executive 
Director of Clinical Research; Dr. Richard O. 
Davies, Director, Clinical Pharmacology; Dr. 
Hubert C. Peltier, Vice-President for Medical 
Affairs; and Mr. Donald S. Brooks of MSDRL 
Legal. A letter of understanding was signed by 
Mr. George M. Norwood, Jr., interim President 
of Thomas Jefferson University, for Jefferson, and 
by Dr. P. Roy Vagelos, President of MSDRL, for 
Merck. 
• Research 
A search committee was formed by the University, 
and in May 1977 Dr. Roger Ferguson was 
recruited to be the first Director. He received his 
medical degree at the University of Utah, then 
served his residency and was an M.S. in 
Pharmacology at the University of Iowa. Dr. 
Ferguson was active in antihypertensive drug 
research at Michigan State University. He had 
recently spent a sabbatical leave with Dr. Hans 
Brunner in Lausanne, Switzerland, where Dr. 
Ferguson undertook the first human investigation 
of a new class of agents, the angiotensin 
converting enzyme inhibitors (ACE inhibitors). 
Dr. Ferguson recruited the initial staff, and the 
first clinical study was undertaken in the fall of 
1977. Peter H. Vlasses, Pharm.D., was appointed 
in 1978 as Assistant Director. Dr. Vlasses received 
his Doctor of Pharmacy degree from the 
Philadelphia College of Pharmacy and Science 
(PCPS); his special interest was in cardiovascular 
drug research. 
Administratively, liaison with the Unit was the 
responsibility of Dr. William B. Abrams, Executive 
Division of Clinical Phannacology • 405 
Director of Clinical Research at Merck. 
Collaboration was initially implemented by Drs. 
David Cooper and Jolm Schrogie through Dr. 
Davies. In 1980, Dr. Abrams asswned rhe liaison 
function directly. Dr. Abrams graduated from 
Jefferson in 1947, interned in Atlantic City, and 
received postgraduate training at the Children's 
Hospital of Philadelphia, Philadelphia General 
Hospital, and Sr. Louis University. I Ie is a past 
President of the American Society for Clinical 
Pharmacology and Therapeutics. Dr. Abrams 
joined Merck in 1975, having previously been 
employed by Ayerst Laboratories and 
Hoffmann-La Rochc, Inc. In order to facilitate the 
arrangements between the institutions, Thomas 
Jefferson University offercd adjunct faculty 
positions to the Merck liaison officers. Thus, Dr. 
Abrams has been Adjunct Professor of Medicine 
since 1977. He received strong support relative to 
this liaison from Marvin E. Jaffe, M.D., 
Vice-President of Clinical Research, who was also 
a Jefferson Medical College graduate and a 
member of the adjunct faculty in neurology. 
The initial direction involved active pursuit of 
ACE inhibitors and expansion of the Division's 
human research capabilities. Over the next several 
years, key personnel additions included Brian N. 
Swanson, Ph.D., Heschi H. Rotmensch, M.D., 
and, in a collaborative arrangement with PCPS, 
Mario L. Rocci, Jr., Ph.D. Dr. Swanson had 
expertise in assay development, especially 
high-performance liquid chromatography. Dr. 
Rotmensch brought expertise in 
pharmacodynamics, whereas Dr. Rocci was skilled 
in pharmacokinetic laboratory and data analysis. In 
this same period, the Unit underwent physical 
expansion, funded by MSDRL, to accomodate 
new laboratory and computer data processing 
facilities. With rhe assembling of this critical mass, 
the Division became very productive in its clinical 
research efforts. 
The evaluation of ACE inhibitors in 
hypertension at Jefferson included dose-response, 
mechanism of action, comparative efficacy, and 
drug interaction studies with captopril, enalapril, 
and lisinopril. The ACE inhibitors subsequently 
have received extensive use in hypertension and 
congestive heart failure. The important Jefferson 
contributions to this field are summarized in a text 
edited by Drs. Ferguson and Vlasses, published 
in 1987. 
Over its ten-year existence, Ij1 studies of new 
compounds were conducted by the Division of 
Clinical Pharmacology. Important contributors 
over this time also included Louis J. Reilly, Jr., 
M.D., and Michael D. Cressman, D.O. A wide 
range of therapeutic categories was represented, 
including diuretics, nonsteroidal anti-inflammatory 
drugs, antibiotics, ophthalmologic agents, and 
psychotl1erapeutic drugs. In general, this was an 
unprecedented period of research productivity in 
this field. 
Many studies at Jefferson characterized the 
pharmacokinctics of the different investigational 
compounds in man. The special emphasis on 
pharmacodynamic assessments in these trials led to 
the development or application of many clinical 
and laboratory drug evaluation techniques. 
Important contributions in healthy volunteer 
experiments includcd the unraveling of the 
differential clinical pharmacology of the 
enantiomers of indacrinone, a uricosuric diuretic, 
and the assessment of systemic beta-blockade after 
dermal and ophthalmic application of timolol and 
other compoundS. Parviz Mojaverian, Ph.D., 
undertook studies with the Heidelberg capsule, a 
pH-sensitive, radiotelemetric device. These studies 
led to important contributions to the 
understanding of the physiology of the 
interdigestive migrating myoelectric complex and 
pharmaceutical considerations dealing with gastric 
indigestible dosage forms (for example, enteric 
coated and sustained-release tablets). The nature 
and mechanism of many drug-drug interactions 
have also been evaluated. Close collaboration 
between Jefferson and Merck clinical and basic 
scientists evolved over this time. Extremely 
efficient processing of studies has resulted, 
facilitated by industrywide innovations in research 
data telecommwlications. To date, well over 125 
research and scholarly publications bearing the 
Jefferson affiliation have resulted from tl1ese 
evaluations. Recent research efforts have 
emphasized drugs affecting the prostaglandins and 
leukotrienes and their involvement in 
inflammation, pain, and local vascular regulation. 
• Education, and Service 
In addition to research efforts, the Division of 
Clinical Pharmacology has participated actively in 
Jefferson Medical College's education and service 
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programs. Since 1977 the Division has offered a 
well-received fourth-year medical student elective 
course in clinical pharmacology employing a 
case-simulation format. Twelve postdoctoral 
(M.D., Ph.D., or Pharm.D.) Fellows as well as 
graduate and undergraduate medical and pharmacy 
students received training in the Division. Many 
faculty held cross-appointments in pharmacology, 
and a close working relationship evolved with 
many physician collaborators and the Hospital's 
Department of Pharmacy, directed by Joe E. 
Smith, Pharm.D. Unit faculty have served as 
teacher for the medical students, provided 
consultation for hospitalized and ambulatory 
patients on drug-related problems, served on 
pertinent comittees (for example, Pharmacy and 
Therapeutics, the Institutional Review Board) and 
have contributed to a variety of community 
services and professional organizations, both 
locally and nationally. In this regard, Dr. Vlasses 
was a founding member of the American College 
of Clinical Pharmacy in 1979, subsequently served 
as national President in 1983, and was honored as 
a Fellow in [985. 
Dr. Ferguson left Jefferson in 1985 to aSSlUue the 
Chair in Medicine at the University of Nevada at 
Reno. Discussions between Jefferson and MSDRL 
officers at that time led to a reaffirmation of the 
commitment of each parry. The desire of both 
institutions was to maintain the activities in 
clinical research and to add investigations of a 
basic and mechanistic nature to this collaborative 
research effort. A revised letter of understanding, 
with funding commitment for a five-year renewal 
period, was executed in 1986. Key figures in tlle 
discussions leading to the continuation agreement 
in addition to Dr. Abrams were Willis C. 
Maddrey, M.D., Chairman of the Department of 
Medicine; Lewis W. Bluemle, M.D., President of 
Thomas Jefferson University; Marvin Jaffe, M.D., 
Vice-President of Clinical Research; and Edward 
Scolnick, M.D., President of MSDRL. 
At this time, the role of the MSDRL Liaison 
was assmned by Dr. Keith H. Jones, Executive 
Director for Clinical Pharmacology. Dr. Jones 
received his medical degree at the University of 
Wales in 1966 and a Diploma in Pharmaceutical 
Medicine from the Royal College of Physicians in 
London in 1976. Prior to coming to MSDRL in 
1979, he was employed by Beecham 
Pharmaceuticals, Surrey, England for ten years. 
Dr. Jones was appointed Adjunct Professor of 
Medicine at Jefferson in 1986. 
A national search by Dr. Maddrey led to the 
recruitment of Thorir D. Bjornsson, M.D. as 
Director of the Division of Clinical Pharmacology 
in 1986. Dr. Bjornsson received his medical degree 
at the University of Iceland. He trained in clinical 
pharmacology at Stanford University and held 
previous faculty positions in clinical pharmacology 
at Duke University. He serves on the 
pharmacology study section of the National 
Institutes of Health. 
As an expression of the commitment to clinical 
pharmacology and the desire to expand the scope 
of Divisional research, Dr. Maddrey provided 
funds for construction of a new Divisional facility 
encompassing II,OOO square feet of laboratory, 
clinical, and office space in the new Medical Office 
Building. The new Divisional facilities opened in 
April, 1987. 
Dr. Bjornsson established three Sections within 
the Division: the Laboratory for Thrombosis and 
Atherosclerosis Research, which he heads; the 
Clinical Research Unit, headed by Dr. Vlasses; 
and the Laboratory for Investigative Medicine, 
headed by Dr. Rocci. Each Section has specific 
interests and functions as well as collaborative 
activities. Merck-funded projects as well as 
research programs funded tllrough other sources 
(federal, foundation, and other pharmaceutical 
companies) are now commonly undertaken by the 
Divisional faculty. Divisional faculty are 
committed to developing a stronger program in 
drug development through clinical and basic 
research and training of future clinical 
pharmacologists. Dr. Bjornsson received a 
prestigious Pharmaceutical Manufacturers' 
Association Development Grant for Clinical 
Pharmacology in 1987 for expansion of the 
Division mission. 
Thus, the decade spanning 1977-1987 has seen 
the evolution of a nationally recognized progranl 
in clinical pharmacology at Jefferson that would 
not have been possible without the strong 
collaborative venture with MSDRL. As the second 
decade begins, enthusiasm runs high for continued 
growth and recognition in an even broader realm 
of research as advances in biotechnology provide 
novel agents for the treatment of human disease. 
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